Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic, NEC Partner on Product Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SomaLogic, which is developing molecular diagnostic tests based on aptamers, and NEC have signed an agreement to explore business opportunities in the life science and healthcare markets, the firms said today.

In addition, NEC has made an equity investment in SomaLogic, though the amount of the investment and other financial terms were not disclosed.

Under the agreement, the two partners will develop and implement applications within NEC's cloud-based services platform "to enhance SomaLogic's products for life sciences research and diagnostics," they said in a joint statement.

Boulder, Colo.-based SomaLogic and NEC plan to integrate SomaLogic's Somamers technology with NEC's Bioprism information management system and other NEC data analysis tools, such as SVM+, a machine learning technique.

The companies did not specify what products would result from their collaboration, but said that customers for applications to be developed would include pharmaceutical firms, research laboratories, and practicing physicians, "with the eventual goal of expanding into personal healthcare services."

SomaLogic's Somamers technology uses aptamers, single-stranded DNA and RNA molecules that bind to specific target molecules with high affinity. According to the company, Somamers can quantify about 1,000 proteins from a drop of blood for the identification of disease-associated biomarkers.

The firm is in the process of developing a lung cancer test using its technology and plans to launch it as a lab-developed test next year.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.